BHC — Bausch Health Companies Inc.

NYSE · Health Care · Pharmaceuticals · CIK 885590 ·
Last close
$6.68
Market Cap
$2.50B
52W High
$7.30
52W Low
$4.33
ADV30
4,398,858
Next earnings
2026-10-28
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 2,524,000,000 1,786,000,000 521,000,000 -1,423,000,000 24,498,000,000 1,299,000,000 25,580,000,000
Dec 2025 2,796,000,000 1,998,000,000 829,000,000 -112,000,000 26,366,000,000 1,309,000,000 25,989,000,000
Sep 2025 2,681,000,000 1,931,000,000 636,000,000 179,000,000 26,824,000,000 1,308,000,000 26,468,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,800,000,000
Investing CF
$-597,000,000
Financing CF
$-1,103,000,000
CapEx
$-407,000,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-2.96
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-10,832,000,000
Inventory
$1,602,000,000
Receivables
$2,263,000,000
ST Investments
EBIT TTM
$875,000,000
Pretax Income TTM
$-732,000,000
Interest Exp TTM
$1,607,000,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$10,853,000,192
EBITDA
$3,908,000,000
Free Cash Flow
$1,433,624,960
Enterprise Value
$22,331,498,496
Total Cash
$1,824,999,936
Total Debt
$20,778,999,808
Shares Out
373,990,561
Trailing EPS
$-2.94
Book Value
$-4.74
ROE
ROA
6.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 10,266,000,000 2,185,000,000 157,000,000 26,366,000,000 25,989,000,000 1,400,000,000
Dec 2024 9,625,000,000 1,854,000,000 -46,000,000 26,523,000,000 26,845,000,000 1,597,000,000
Dec 2023 8,757,000,000 1,600,000,000 -592,000,000 27,350,000,000 27,432,000,000 1,032,000,000
Dec 2022 8,124,000,000 1,391,000,000 -225,000,000 25,686,000,000 25,426,000,000 -728,000,000

TTM Snapshot

Revenues TTM
$8,905,000,000
NetIncome TTM
$124,000,000
OpCashFlow TTM
$0
Assets (Latest)
$26,523,000,000
Forward EPS
$4.19

Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.00 · spot: $6.68 · call volume: 60 · put volume: 2,021
Expected Move to 2028-01-21: ±$3.50 (52.40%) — implied range $3.18$10.18 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NKTR NEKTAR THERAPEUTICS $2.52B $73.69
PBH Prestige Consumer Healthcare Inc. $2.46B $52.02
RARE Ultragenyx Pharmaceutical Inc. $2.54B $25.72
PGEN PRECIGEN, INC. $2.56B $7.17
VERA Vera Therapeutics, Inc. $2.43B $33.72

News headlines (Yahoo Finance, 1h cache)

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
2026-08-17 12:00 · Yahoo
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
2026-08-10 20:26 · Yahoo
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
2026-08-06 11:04 · Yahoo
(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
2026-07-28 12:00 · Yahoo
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
2026-08-21 16:20 · Yahoo
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
2026-08-21 16:00 · Yahoo
Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook
2026-07-31 04:03 · Yahoo
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
2026-07-30 16:33 · Yahoo
Bausch Health Companies Inc. Q2 2026 Earnings Call Summary
2026-07-30 12:30 · Yahoo
Bausch Health Cos Q2 Earnings Call Highlights
2026-07-30 01:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.